A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This study will evaluate the efficacy and safety of atezolizumab compared with placebo as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Inclusion Criteria
Exclusion Criteria:
La Jolla, California 92093, United States
Marietta, Georgia 30060, United States
Shanghai, 200011, China
Wuhan, 430023, China
Bonn, 53127, Germany
München, 81377, Germany
Rostock, 18059, Germany
Naples, Campania 80131, Italy
Meldola, Emilia-Romagna 47014, Italy
Rome, Lazio 00161, Italy
Milan, Lombardy 20133, Italy
Hokkaido, 060-8648, Japan
Gliwice, 44-101, Poland
Warsaw, 02-781, Poland
Krasnoyarsk, Krasnodarskiy Kray 660133, Russia
Moscovskaya Oblast, Moscow Oblast 143423, Russia
Moscow, Moscow Oblast 105229, Russia
Moscow, Moscow Oblast 125248, Russia
Moskva, Moscow Oblast 119435, Russia
Moskva, Moscow Oblast 125367, Russia
Saint Petersburg, Sankt-Peterburg 197758, Russia
Yekaterinburg, Sverdlovsk Oblast 620905, Russia
Taichung, 404, Taiwan
Zhongzheng Dist., 10048, Taiwan
Kar?iyaka, 35575, Turkey (Türkiye)
Kharkiv, Kharkiv Governorate 61070, Ukraine
Kiev, 03115, Ukraine
Kryvyi Rih, 50048, Ukraine
Lviv, 79031, Ukraine